Insight Molecular Diagnostics Inc.
Price Action
Technical Summary
CONSOLIDATINGInsight Molecular Diagnostics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 70), indicating performance broadly in line with the market. Earnings growth of 54% provides fundamental context to the price action. Investors should exercise caution due to high volatility (105% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.53 | -10.86% | BELOW |
| 50 SMA | $5.45 | -9.62% | BELOW |
| 100 SMA | $4.95 | -0.48% | BELOW |
| 150 SMA | $5.41 | -8.85% | BELOW |
| 200 SMA | $5.37 | -8.11% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IMDX in an uptrend right now?
IMDX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is IMDX overbought or oversold?
IMDX's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is IMDX outperforming the market?
IMDX has a Relative Strength (RS) Rating of 70 out of 99. IMDX is performing about average compared to the market.
Where is IMDX in its 52-week range?
IMDX is trading at $4.93, which is 58% of its 52-week high ($8.51) and 42% above its 52-week low ($2.33).
How volatile is IMDX?
IMDX has a Beta of 2.38 and 52-week volatility of 105%. It's more volatile than the S&P 500 - expect bigger swings.